Cases & Deals

  • Home
  • Practices
  • METiS Pharmaceuticals develops global patent portfolios related to lipid nanoparticles for mRNA-based gene therapies

Share

METiS Pharmaceuticals develops global patent portfolios related to lipid nanoparticles for mRNA-based gene therapies

November 2023

Client(s) METiS Therapeutics, Inc.

Jones Day is representing METiS Pharmaceuticals, Inc. in connection with the establishment of global patent portfolios related to lipid nanoparticles (LNP) and uses thereof in various mRNA-based gene therapies. METiS focuses on leveraging artificial intelligence (AI), machine learning (ML), and molecular dynamics (MD) to develop novel therapeutics in the small molecule and advanced nucleic acid spaces. METiS' lead programs use AI and high-throughput in vivo screening to discover unique LNPs with world class capabilities. This engine has resulted in LNPs that can target multiple organ systems with high delivery efficiency and clean safety profiles.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.